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Introduction: Recruitment and nodule management are critical 
issues of lung cancer screening with low-dose computed tomog-
raphy (LDCT). We report subjects’ compliance and results of 
LDCT screening and management protocol in the active arm of the 
ITALUNG trial.
Methods: Three thousand two hundred six smokers or former smok-
ers invited by mail were randomized to receive four annual LDCT 
(n = 1613) or usual care (n = 1593). Management protocol included 
follow-up LDCT, 2-[18F]fluoro-2-deoxy-D glucose positron emis-
sion tomography (FDG-PET), and CT-guided fine-needle aspiration 
biopsy (FNAB).
Results: One thousand four hundred six subjects (87%) underwent 
baseline LDCT, and 1263 (79%) completed four screening rounds. 
LDCT was positive in 30.3% of the subjects at baseline and 15.8% sub-
sequently. Twenty-one lung tumors in 20 subjects (1.5% detection) were 
found at baseline, and 20 lung tumors in 18 subjects (0.5% detection) 
in subsequent screening rounds. Ten of 18 prevalent (55%) and 13 of 17 
incident (76%) non–small-cell cancers were in stage I. Interval growth 
enabled diagnosis of lung cancer in 16 subjects (42%), but at least one 
follow-up LDCT was obtained in 741 subjects (52.7%) over the screen-
ing period. FDG-PET obtained in 6.5% of subjects had 84% sensitiv-
ity and 90% specificity for malignant lesions. FNAB obtained in 2.4% 
of subjects showed 90% sensitivity and 88% specificity. Positivity of 
both FDG-PET and FNAB invariably predicted malignancy. Surgery 
for benign lesions was performed on four subjects (10% of procedures) 
but followed protocol violations on three subjects.
Conclusions: High-risk subjects recruited by mail who entered LDCT 
screening showed a high and stable compliance. Efficacy of screening 
is, however, weakened by low detection rate and specificity. Adhesion 
to management protocol might lessen surgery for benign lesions.
Key Words: Cancer, Computed tomography, Nuclear medicine, 
Pulmonary biopsy.
(J Thorac Oncol. 2013;8: 866-875)
In Western countries, lung cancer is the most common malignant neoplasm in men, and its frequency is constantly 
increasing in women.1 Non–small-cell lung cancer (NSCLC) 
accounts for approximately 85% of these neoplasms.2,3 
Although the age-adjusted trends of mortality are decreasing, 
survival rates for lung cancer are still 10% to 16%.4,5 In par-
ticular, only 15% to 20% of symptomatic patients have lesions 
amenable to radical surgical resection.6
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Randomized clinical trials (RCTs) with chest radio-
graph as screening test for lung cancer failed to show any ben-
efit in smokers and former smokers because of an excess of 
deaths in the screened arm. This was presumably because of 
the high number of surgically resected cancers with associated 
side effects and unnecessary surgical procedures for indolent 
cancers in the active arm.7–10
After publication of the Early Lung Cancer Action 
Project (ELCAP) study results in 1999,11 several observational 
(one-arm) studies assessed the performance of low-dose com-
puted tomography (LDCT) as a screening tool for lung cancer 
in at-risk individuals.12 The largest observational study, the 
International-ELCAP study,13 confirmed the high sensitivity 
of LDCT as a screening test and reported a 88% 10-year sur-
vival rate after surgical resection in screen-detected stage I 
lung cancers. However, observational studies are insufficient 
to establish the efficacy of a screening test in reducing tumor-
specific mortality because they suffer from lead time, length, 
and overdiagnosis bias.14–16
Accordingly, several RCTs for lung cancer screen-
ing with LDCT have been implemented in United States 
and Europe.17–25 In 2011, the largest RCT in United States, 
namely the National Lung Screening Trial (NLST),26 was 
halted because an interim analysis after 8 years of follow-up 
showed a 20% mortality reduction in the screened arm receiv-
ing annual LDCT for three rounds as compared with control 
arm receiving annual chest radiograph for three rounds.27 The 
result of the NLST is the first one supporting the efficacy of 
LDCT as a screening test in reducing mortality from lung 
cancer in high-risk individuals, and has considerably renewed 
interest and enthusiasm, as also criticisms28–30 about the pos-
sibility of offering LDCT on a large scale to smokers and for-
mer smokers. The latter has been recently recommended31,32 
despite the negative short-term results concerning decrease of 
mortality of three small RCTs in Europe.18,33,34
Variable approaches concerning subjects recruit-
ment, timing and reading of the LDCT screening test, and 
the protocol for management of screen-detected suspicious 
nodules were proposed.18,21,25,27,35–37 Comparative analyses of 
the different studies are fundamental for a thorough evalu-
ation of efficacy of the screening procedure. To date, the 
complete, namely during the entire screening period, per-
formance of both LDCT as a screening test and the manage-
ment strategy for suspicious nodules was reported in five 
RCTs, namely the Lung Screening Study,38 the NLST,27 the 
DANTE and MILD trials in Italy,18,33 and the Danish Lung 
Cancer Screening trial.34,37
The Italian Lung (ITALUNG) study is an RCT part 
of an international cooperation, aimed at the pooled evalu-
ation of the results of the RCTs of lung cancer screening 
with LDCT in Europe and possibly United States.39 The 
ITALUNG study design, enrolment procedure, and the 
results of the baseline screening round were previously 
reported.20 Herein, we present the final data concerning the 
compliance of the subjects recruited in the active arm of 
the trial, who were invited to undergo four annual LDCT, 
the results of the LDCT screening test in the four screening 
rounds, and the results of management protocol for screen-
detected suspicious nodules.
MATERIALS AND METHODS
ITALUNG is an RCT aimed to evaluate the efficacy of 
chest LDCT as a screening test in reducing lung cancer mor-
tality, which is carried out in the Tuscany region of Italy.
The study was conducted in accordance with the 
amended Declaration of Helsinki (http://www.wma.net/
en/30publications/10policies/b3/) and approved by the Local 
Ethic Committees of the participating institution (approval 
number 29–30 of September 30, 2003; number 23 of October 
27, 2003; and number 00028543 of May 13, 2004).
Selection and Randomization 
of Study Participants
Strategy and results of the exclusive mail recruitment 
of trail participants were previously reported.20 Those eligible 
for the trial were asymptomatic smokers and formers smok-
ers aged 55 to 69 years, with a smoking history of at least 
20 pack-years, and no history of cancer, other than nonmela-
noma skin cancer, or general conditions precluding thoracic 
surgery.
Subjects randomized to the control arm received a let-
ter communicating their allocation in the usual care arm of 
the study, in which no LDCT or chest radiograph is sched-
uled. Subjects randomized into the active arm were con-
tacted by phone to fix an appointment for counseling, during 
which a pneumonologist, after providing further informa-
tion about the screening LDCT examination and manage-
ment of positive screening tests, collected the consent for 
LDCT examination, and scheduled the LDCT screening test. 
An additional written consent for enrolment in a biomark-
ers-collateral study was requested during the interview.40 A 
free-access invitation for a smoking cessation program was 
provided to smokers enrolled both in the active and in the 
control arms.
All randomized subjects are planned for follow-up 
by cancer registry of the Tuscany region (http://www.ispo.
toscana.it) for 7 years from randomization, to assess incidence 
of lung cancer and mortality from lung cancer or other causes. 
Although no specific instruction about the workup of cases 
of lung cancer in the control arm was provided to general 
practitioner or the enrolled subject, the low rate of migration 
of patients, who receive a diagnosis of primary lung cancer in 
the Tuscany region (< 3%, personal unpublished observation, 
2011 ), makes it probable that they will be referred in the same 
structures participating in the ITALUNG trial. Because the 
management of the suspicious nodules in the ITALUNG trial 
is derived by the clinical practice (see below), it is expected 
that no major discrepancies will be active in the workup, 
diagnosis, and staging of such cases, and that the related 
information will be available and gathered from hospital 
chart recordings at the end of the study. The first mortality 
data concerning the subjects enrolled in the ITALUNG are 
expected for 2014.
The present report is based on the data of the subjects 
randomized to the active arm of the trial, who underwent 
baseline LDCT and were invited again for the next three 
annual repeat LDCT examinations. Individuals in whom lung 
cancer was diagnosed were not offered subsequent screening 
rounds.
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Procedure and Instrument of Screening
The LDCT examinations were obtained in the three 
screening centers on eight different spiral scanners, which 
included one with a single row of detectors, and seven with mul-
tiple rows of detectors (3 with 4, 2 with 16, and 2 with 64 rows). 
The following technical parameter ranges were selected to con-
tain the radiation dose: 120 to 140 kV, 20 to 43 mAs, pitch 1 to 
2. The section collimations ranged between 3 mm in the single-
detector scanner, and 0.75 mm in the 64-row detector scanner.
Because double reading increases the sensitivity of 
LDCT screening,41 each LDCT examination was assessed on 
a workstation independently by two of 17 certified radiolo-
gists having at least 5 years of experience in chest computed 
tomography (CT). A consensus between the two radiologists 
was reached in case of disagreement. All previous LDCT 
examinations of the subject obtained in the context of the 
trial were available for comparison. Management of posi-
tive screening tests was carried out at each screening cen-
ter according to a shared protocol,20 which is fundamentally 
derived from that of the International-ELCAP Study.35 This 
includes follow-up LDCT with or without 1 month of antibi-
otic therapy, chest 2-[18F]fluoro-2-deoxy-D glucose positron 
emission tomography (FDG-PET), and CT-guided fine-needle 
aspiration biopsy (FNAB). Optical fibrobronchoscopy (FBS) 
was also performed on selected cases.
The FDG-PET examinations were performed in three 
centers using four scanners, two of which were dedicated 
positron emission tomographs (one GE Advance positron 
emission tomography [PET] scanner; General Electric, 
Milwaukee, WI; one ECAT Exact HR+ scanner; Siemens, 
Erlangen, Germany), and two dual-modality PET-CT scanners 
(1 Discovery LS; General Electric, Milwaukee, WI; 1 Gemini; 
Philips, Eindhoven, The Netherlands). Three trained nuclear 
medicine physicians visually evaluated the tracer uptake of the 
suspicious lesion and classified the result of the FDG-PET as 
positive, indeterminate (mild or faint FDG uptake, typically 
similar to that of mediastinum), or negative. Because most of 
the nodules to be investigated were of small size, we did not 
use the standardized uptake value because it can be unreliable 
in characterizing nodule uptake.37.42 Moreover, taking into con-
sideration that tumors identified at lung cancer screening with 
LDCT can show low FDG uptake,42,43 for the purpose of compu-
tation of performance of FDG-PET, we assimilated indetermi-
nate to positive FDG-PET results.
The majority (35 of 38) of the CT-guided FNAB was 
performed by two experienced interventional radiologists on a 
single-detector spiral CT scanner (Somatom plus 4; Siemens, 
Erlangen, Germany) used for the LDCT examination in one 
screening center, where aspiration material was evaluated by 
one trained cytopathologist, with rapid onsite examination 
(ROSE) technique.44,45 Three CT-guided FNAB without ROSE 
were performed by a chest radiologist on a four-detector spi-
ral CT scanner (Somatom Volume Zoom; Siemens, Erlangen, 
Germany) used for LDCT examination in another screening 
center. For the purpose of computation of performance of 
CT-guided FNAB, we assimilated inconclusive results because 
of inadequate or insufficient material to negative FNAB.
Criteria for Positive Test and Further 
Diagnostic Investigations
Positivity of the LDCT screening test was fundamen-
tally based on the nodule size or growth measured in terms 
of mean diameter, which was manually computed by the radi-
ologist with electronic callipers on workstations.20 In particu-
lar, significant growth was defined as an increase of at least 
1 mm in mean diameter of a solid or nonsolid nodule, taking 
into account the intra- and interoperator variability in measur-
ing mean diameter of solid nodules,46 or the appearance or 
increase of a solid component in a nonsolid or part-solid nod-
ule in two successive LDCT examinations.35 The criteria for 
positive tests and further diagnostic investigations concern-
ing baseline screening round were previously detailed.20 At 
annual repeat screening rounds, the LDCT examination was 
considered positive if either a new solid, part-solid or nonsolid 
nodule was identified, or at least one solid, part-solid or non-
solid nodule already present in the last LDCT showed interim 
growth. If the new nodule had a mean diameter 3 mm or less, 
the subject received a 6-month follow-up LDCT, whereas 
a 3-month follow-up LDCT was obtained in case of a new 
nodule with mean diameter between 3mm and 5mm. In case 
of a nodule that was 5 mm or more in size, or if the screen-
ing test revealed multiple focal solid or nonsolid abnormali-
ties consistent with inflammatory disease, a follow-up LDCT 
after 1 month of antibiotic therapy was recommended. In case 
of complete resolution of the abnormalities, the subject was 
sent for annual repeat screening, whereas, a further follow-up 
LDCT after 2 months was performed in case of partial or lack 
of resolution after antibiotic therapy.
When a solid nodule observed at baseline or repeat 
screening round attained a mean diameter 8 mm or more, and 
persisted after antibiotic therapy, chest FDG-PET examination 
was recommended. However, in some cases of large lesions, 
strongly suggestive for malignancy, CT-guided FNAB 
or FBS were directly performed. For FDG-PET–positive 
nodules, a CT-guided FNAB with ROSE was recommended, 
whereas, a further 3-month follow-up LDCT was obtained in 
FDG-PET–indeterminate or –negative nodules. A 3-month 
follow-up LDCT was also scheduled for nodules with positive 
or indeterminate FDG-PET and negative or inconclusive 
CT-guided FNAB. All subjects showing no nodule growth 
at this latter follow-up LDCT were invited to the subsequent 
annual repeat LDCT scan. For pure nonsolid noncalcified 
nodules of at least 10 mm diameter at baseline, and for new 
or growing nonsolid or part-solid nodule of at least 8 mm 
diameter at annual repeat screening, which persisted after 
antibiotic therapy, CT-guided FNAB was scheduled because 
FDG-PET is not indicated.47
All subjects with FNAB evidence of malignancy under-
went a staging full-dose chest CT examination, with intra-
venous iodinated contrast administration extended to upper 
abdomen and head. Surgery was recommended for nodules 
with findings consistent with malignancy at FNAB and also 
in subjects with an FDG-PET–positive solid nodule, which 
was inconclusively evaluated at FNAB. All the surgically 
removed lesions were evaluated according to the World Health 
Organization criteria.48 Staging of screen-detected lung can-
cer was based on the pathology report when available, or on 
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clinical and contrast-enhanced CT findings in the cases not 
amenable to surgical resection.
Sputum and blood samples were obtained from each 
participant at baseline LDCT screening test and again in case 
of positive LDCT examination; all the samples were stored for 
subsequent biomarker evaluation.40 The global and individual 
radiation dose to subjects recruited in the active arm of the 
ITALUNG trial has been previously reported.49
RESULTS
One thousand six hundred thirteen subjects (1035 men 
and 578 women; mean age = 60.7 years; mean pack-years = 
42.9; 553 former smokers) were randomized to the active arm, 
and 1593 (1039 men and 554 women; mean age = 61.0 years; 
mean pack-years = 41.6; 575 former smokers) to the control 
arm. The first baseline LDCT was obtained in March 2004 and 
the last annual LDCT examination in February 2010. Table 
1 summarizes the compliance of the subjects randomized to 
the active arm, the results of the screening LDCT, the nod-
ule management, and the screen-detected NSCLC in the four 
screening rounds of the ITALUNG trial.
One thousand four hundred six (910 men with a mean 
age of 61.1 years and 496 women with a mean age of 60.6 
years) of the subjects (87.1%) randomized to the active arm 
underwent the baseline LDCT. After exclusion from the next 
round of invitation of subjects in whom the screening proce-
dure revealed lung cancer, 1356 (85.1%) executed the second, 
1308 (82.3%) the third, and 1263 (79.8%) the fourth annual 
screening round with LDCT.
LDCT was positive in 30.3% at baseline and 15.7% 
(range, 13.7–17.3%) at the three annual repeat screening 
rounds (Table 1). Twenty-one cancers (18 NSCLC, 1 carcinoid, 
2 small-cell lung cancers [SCLCs]) were found in 20 subjects 
at baseline screening round (prevalent cancers detection rate 
1.5%), and 20 (17 NSCLC, 2 carcinoid, 1 SCLC) cancers in 
18 subjects at the third annual repeat screening rounds (mean 
incident cancers detection rate 0.5%). Adenocarcinoma (AC) 
accounted for nine of 18 (50%) of the NSCLCs at baseline 
and for 15 of 17 (88%) at subsequent annual repeat screening 
rounds. Three subjects of 38 (7.8%) in whom lung cancers 
were screen detected had two malignant lung tumors. One had 
AC in right lung and SCLC (limited disease) in the left lung, 
one had AC in the right lung and a carcinoid in the left lung, 
and one had AC in the right lung and AC with bronchiole-
alveolar features in the left lung. Isolated lung metastases 
(from gastrointestinal and renal cancer, 2 each) were detected 
by LDCT in four subjects during the entire screening cycle. 
Two interval cancers, namely lesions that were diagnosed 
outside the screening frame, were observed in the active arm 
during the screening period: one SCLC with extensive disease 
diagnosed between the second and third screening rounds, and 
one stage IV NSCLC diagnosed between the third and fourth 
screening rounds.
The characteristics of the screen-detected primary lung 
cancers found at baseline and annual repeat LDCT screening 
rounds are reported in Supplemental Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A409). Excluding 
two SCLCs and one large hilar mass, the average mean diam-
eter of the screen-detected tumors was 24.2 mm at baseline, 
TABLE 1.  Compliance of Subjects Randomized to the Active Arm, Results of the Four Screening Rounds with LDCT, Nodule 
Management, and Lung Cancers in the ITALUNG Trial
T0 T1 T2 T3 T1–T3 T0–T3
Subjects invited 1613 1593 1589 1581
LDCT executed 1406 −87.10% 1356 −85.10% 1308 −82.30% 1263 −79.80% 3927 5333
Positive LDCT test 426 −30.30% 234 −17.30% 211 −16.10% 173 −13.70% 618 −15.80%
Follow-up LDCT 366 225 202 173 600 966
 1 month 31 27 30 32 89 120
 3 months 335 163 132 115 410 745
 6 months 0 35 40 26 101 101
FDG-PETa 60 15 15 12 42 102
 Positive 14 7 7 4 18 32
 Indeterminate 2 1 2 2 5 7
 Negative 44 7 6 6 19 63
CT-guided FNABb 18 6 5 9 20 38
 Positive 12 5 4 7 16 28
 Negative 3 1 0 2 3 6
 Inadequate 3 0 1 0 1 4
Lung cancersc 18 2 9 6 17 35
 Stage I 10 2 6 5 13 23
 Stage II–IV 8 0 3 1 4 12
aNinety-seven FDG-PET examinations were obtained in 92 subjects for 102 target lesions.
bThirty-eight CT-guided FNAB were obtained in 34 subjects for 38 lesions.
cThree carcinoids and three small-cell lung cancers excluded—pathological or clinical stage.
CT, computed tomography; FDG-PET, 2-[18F]fluoro-2-deoxy-D glucose positron emission tomography; FNAB, fine-needle aspiration biopsy; LDCT, low-dose computed 
tomography.
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and 17.3 mm at subsequent annual screening rounds (p = not 
significant). Ten (56%) of the 18 prevalent NSCLCs were in 
stage I (8 in stage IA and 2 in stage IB) as compared with 13 
of the 17 incident NSCLCs (76%) (11 in stage IA and 2 stage 
IB) (p = not significant) (Table 1).
As part of management of positive screening tests, 966 
(120 after 1 month of antibiotic therapy, 745 after 3 months, 
and 101 after 6 months) follow-up LDCT examinations were 
obtained. They accounted for 15% (966 of 6299) of the total 
number of LDCT examinations performed in the active arm 
of the ITALUNG trial. Seven hundred forty-one of the 1406 
subjects (52.7%) who underwent the baseline LDCT had at 
least one positive LDCT examination for noncalcified nodule 
over the entire screening cycle. Lung cancer was diagnosed 
in 16 of 38 subjects (42%) after evidence of lesion growth at 
follow-up LDCT examinations. Nodule disappearance or size 
reduction at LDCT after 1 month of antibiotic therapy was 
observed in 80 of 120 subjects (67%) (in 11 of 31 subjects 
[35%] at baseline and 69 of 89 subjects [77%] at annual repeat 
screening rounds).
Ninety-seven chest FDG-PET examinations were 
obtained in 92 subjects, namely 6.5% of the subjects ran-
domized to the active arm who underwent baseline LDCT. 
Five subjects had two FDG-PET each. Fifty-seven PET-
FDG examinations were performed at baseline, and 40 at 
subsequent annual screening rounds. Thirty-eight primary 
(n = 35) or secondary (n = 3) lung cancers were ultimately 
diagnosed in 35 subjects (3 subjects had 2 lesions, 1 a mixed 
cancer and SCLC, 1 a carcinoid and AC, and 1 subject had 
an AC and a controlateral early AC). On a total of 102 tar-
get lesions in 92 subjects (84 subjects had a single lesion and 
were examined once, 5 subjects had a single lesion and were 
examined twice, 2 subjects had 2 lesions and were examined 
once, and 1 subject had 2 lesions and was examined twice) 
and assimilating to positive the seven indeterminate FDG-
PET results, which corresponded to lung cancer in six, the 
overall sensitivity of FDG-PET was 84% and specificity 89% 
(Table 2). Overall sensitivity and specificity assimilating inde-
terminate FDG-PET to negative results were 68% and 90%, 
respectively.
Thirty-eight CT-guided FNAB (with ROSE in 34) were 
obtained in 38 lesions in 34 subjects, that is, 2.4% of sub-
jects randomized to the active arm who underwent baseline 
LDCT. In four subjects, two CT-guided FNAB were performed 
on two distinct lesions. Eighteen FNAB were performed on 
lesions detected at baseline screening round and 20 on lesions 
detected at subsequent annual screening rounds. The mean 
diameter of the nodules referred to FNAB was 18.2 mm (range, 
5–48). Overall, 34 of 38 (89%) procedures yielded adequate 
material for the cytological examination (Table 2). CT-guided 
FNAB was positive and histological examination of the sur-
gical specimen revealed lung cancer (n = 25) or metastasis 
(n = 2) in 27 of 38 (71%) lesions and atypical adenomatous 
hyperplasia (AAH) in one lesion. CT-guided FNAB was nega-
tive in six subjects (with lung cancer in 1 subject) and inconclu-
sive in four subjects (with lung cancer and renal metastasis in 1 
subject each). By assimilating the inconclusive to the negative 
FNAB results, the overall sensitivity of FNAB was 90% and 
specificity 88%. Sensitivity was 96% and specificity 83% after 
exclusion of the inconclusive FNAB for insufficient material. 
Pneumothorax occurred in 11 of 38 (29%) of the procedures, 
but only two subjects (5%) needed thoracic drainage.
FBS was obtained in 30 subjects, that is, 2.1% of the 
subjects who underwent baseline LDCT screening. Twenty 
were performed at baseline and 10 at the subsequent screening 
rounds. FBS was positive in eight subjects (all with lung can-
cer) and negative in 22 subjects. In six subjects with negative 
FBS, a diagnosis of lung cancer was finally reached. Overall 
sensitivity of FBS was 57% and specificity 100%.
Twenty-eight subjects received both FDG-PET and 
CT-guided FNAB as part of management of suspicious nodules. 
Positivity of both FDG-PET and CT-guided FNAB enabled pre-
diction of lung malignancy in all 18 subjects with such a com-
bination of results. In particular, primary lung cancer was found 
in 16 cases and solitary metastases (from gastrointestinal can-
cers) in two cases. FDG-PET and CT-guided FNAB were both 
negative in four subjects without lung cancer. Discrepancies 
between the results of FDG-PET and CT-guided FNAB were 
observed in six cases. In three subjects with final diagnosis of 
lung cancer, FDG-PET was positive and CT-guided FNAB was 
negative. However in one of the three subjects, because of the 
deep location of the nodule, the negative FNAB was performed 
under transoesophegeal ultrasound guidance rather than under 
CT guidance. In one additional subject with a final diagnosis 
of lung cancer FDG-PET was negative and CT-guided FNAB 
was positive. In the two final subjects in whom no lung can-
cer was ultimately diagnosed during the screening period, the 
FDG-PET was positive and the CT-guided FNAB was negative 
in one case, and the FDG-PET was negative and the CT-guided 
FNAB was inconclusive in the other.
Six subjects with final diagnosis of lung cancer did not 
undergo FDG-PET. Three of them had large cancers (diam-
eter range, 35–48 mm) detected at baseline screening round, 
for which the protocol enabled direct CT-guided FNAB. Two 
subjects had cancers appearing as a part-solid nodule with a 
very small solid component at annual repeat screening rounds, 
which directly underwent CT-guided FNAB. One final sub-
ject had a small peripheral solid nodule at baseline screen-
ing, which exhibited significant growth at follow-up, and also 
directly underwent CT-guided FNAB.
Eight subjects with final diagnosis of lung cancer did 
not undergo CT-guided FNAB. Five subjects with histological 
lung malignancy (4 NSCLC and 1 metastasis from renal 
cancer) had a positive FDG-PET and were directly sent to 
surgery as well as two subjects with carcinoid who had an 
indeterminate or negative FDG-PET, and one final subject 
with metastasis from renal cancer and negative FDG-PET.
Therapy of screen-detected primary lung cancers 
included surgery (lobectomy n = 29; sublobar resection n = 6; 
pneumonectomy n = 1) in 34 subjects with lung cancer (30 
with NSCLC, 3 with carcinoids, and 1 with both NSCLC and 
SCLC) alone (n = 29), or in combination with both chemo 
and radiation therapy (n = 3) or just chemotherapy (n = 2). Six 
subjects with primary lung cancers did not receive surgery. 
Two subjects were treated with combined chemo and radiation 
therapy and four with chemotherapy alone.
Surgical resection for benign lung pathology was car-
ried out in four subjects, corresponding to 10% (4 of 38) of the 
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subjects undergoing surgical resections of lung lesions detected 
by LDCT screening. Three of them followed violations of the 
management protocol. In particular, the first subject was referred 
to surgery without undergoing FDG-PET or CT-guided FNAB 
because a comparison between the baseline LDCT and a prior 
chest CT performed for other reasons 2 years before enrolment 
in the trial showed increase of the mean diameter of a solid 
nodule from 5 mm to 8 mm. Histological examination revealed 
hamartocondroma. The second subject showed a new part-
solid nodule of 10-mm mean diameter at the last annual repeat 
screening round, which doubled its diameter at 3-month follow-
up LDCT. The lesion was positive to FDG-PET and was surgi-
cally removed without preliminary CT-guided FNAB. Surgical 
pathology failed to identify malignant cells. The third subject 
underwent surgery for a solid lesion positive to FDG-PET and 
CT-guided FNAB in the right upper lung, which increased in 
mean diameter from 6 mm to 9 mm in the last annual repeat 
screening round, and which on pathological examination was 
found to be an AC. However, during the same surgical session 
the thoracic surgeon also decided to resect a purely nonsolid 
nodule of 10 mm in diameter in the right inferior lobe, which 
was not previously evaluated with FNAB, and whose pathol-
ogy showed it to be AAH. The fourth subject underwent sur-
gical removal of a nonsolid nodule that showed an increased 
diameter from 8 mm to 12 mm mean diameter from baseline 
to second annual repeat screening round with indeterminate 
FDG-PET and positive CT-guided FNAB, but the histological 
diagnosis also in this case was AAH.
Five extrapulmonary malignancies (2 cases of malig-
nant mesothelioma, 1 of primary breast cancer, 1 of primary 
kidney cancer, and 1 thymoma) were detected in the subjects 
of the arm undergoing LDCT screening.
DISCUSSION
Comparative analyses of the recruitment strategies, 
subjects’ compliance, performance of LDCT as screen-
ing test, and management protocols for suspicious nodules 
are fundamental for a thorough evaluation of efficacy and 
cost effectiveness of the screening procedure of lung cancer 
with LDCT in at-risk populations and for its standardization. 
Moreover, they are mandatory before data pooling of RCTs.
Different from all other observational studies12 and 
several RCTs17,18,21,27 that recruited volunteers in response to 
advertisements in the media implying a selection bias, we 
recruited participants to the ITALUNG trial by direct mailing 
to subjects potentially at high risk of lung cancer because of 
age and smoking history.20 A similar recruitment procedure 
was adopted in the Dutch-Belgian Lung Cancer Screening 
Trial (NELSON) and German trials.19,24 In general, this 
procedure follows the one used in the Tuscany region of Italy 
for population screening of breast cancer with mammography, 
and of colorectal cancer with fecal occult blood test; both 
involved direct mailing to registered residents. Admittedly, the 
overall 23.9% adhesion in terms of replies to mail invitation 
in the ITALUNG trial is lower than the 32% to 33% reported 
in the NELSON and German trial,19,24 and much lower than 
that of breast (60–70%)50 and colorectal screening (56%) 
in Tuscany.51 In our opinion, besides general reasons for 
nonattendance to cancer screening procedures, including 
distrust in medicine and screening and a sense of fatality 
about diseases, two additional reasons for the lower adhesion 
to the mail invitation in the ITALUNG trial are the unproven 
efficacy of the LDCT screening at the time of enrollment 
(2004–2006), and the possibility of being randomized in the 
control arm receiving usual care. Further information about 
the experience of the participants to the ITALUNG trial is 
being collected with follow-up questionnaires.
We observed a high and sustained compliance of the 
subjects randomized to the active arm, with a 79% propor-
tion of the subjects that completed four annual LDCT rounds. 
Notably, the greatest drop out (12.8%) in the active arm of 
our study occurred between the consensus to be randomized 
and execution of the baseline LDCT, which is similar to what 
was observed in the Depiscan (12.7%)52 and in the Detection 
and Screening of Early Lung Cancer by Novel Imaging 
Technology and Molecular Essays (DANTE) (19%)33 RCTs, 
but remarkably higher than in the NLST (2.6%)27 and Danish 
(0.2%)34 RCTs. In our opinion, this phenomenon is presum-
ably because of our study design, in which we first obtained 
the participant’s consent to the randomization and then invited 
the eligible subjects allocated to the active arm to LDCT test-
ing. In the period between compilation of the questionnaire 
for eligibility and the date of the LDCT, these subjects might 
have elaborated their fear and anxiety about the screening 
procedure, especially after explanation during the preliminary 
counseling of the screening procedure with LDCT and of the 
probability of obtaining a false-positive test, which would 
require further possibly invasive investigations in absence 
of a lung cancer.12 This detailed information could have the 
effect of discouraging subjects passively recruited by mail,23 
and ultimately determine decline in the test appointment. This 
mechanism is unlikely to occur in studies recruiting volun-
teers, and indicates that further investigation is worthwhile to 
improve the communication with high-risk subjects.
In our study, 90% of the subjects who executed base-
line LDCT completed the four screening rounds. The final 
TABLE 2.  Results of FDG-PET and CT-Guided FNAB in the 
ITALUNG Triala
Screening
True-
Positive
True-
Negative
False-
Positive
False-
Negative TotalRound
FDG- 
PET Baseline 16 40 0 4 60
Repeat 16 17 7 2 42
Total 32 57 7 6 102
CT-
guided
FNAB Baseline 10 3 0 1 14
Repeat 17 4 1 2 24
Total 27 7 1 3 38
aThe seven nodules showing faint FDG uptake qualifying for indeterminate PET 
result were considered as positive, and the four nodules whose FNAB was not diagnostic 
were considered as negative.
CT, computed tomography; FDG-PET, 2-[18F]fluoro-2-deoxy-D glucose positron 
emission tomography; FNAB, fine-needle aspiration biopsy.
872 Copyright © 2013 by the International Association for the Study of Lung Cancer
Pegna et al. Journal of Thoracic Oncology®  •  Volume 8, Number 7, July 2013
79% compliance was higher than those in several observa-
tional studies and RCTs,12 but lower than those in the Lung 
Screening Study (LSS) (84% at the second year),38 NLST 
(90% at the third year),27 Multicentric Italian Lung Detection 
(MILD) (95% and 96%),18 and Danish trial (90% at the fifth 
year),34 which, however, recruited volunteers. The adhesion 
and compliance rates in the ITALUNG trial might constitute 
valuable reference terms for future screening programs of 
lung cancer with LDCT involving population-based invita-
tion (by mail or counseling) of subjects at high risk of lung 
cancer. In the active arm of the ITALUNG trial we observed a 
low rate of screen-detected lung cancers, which were mostly 
represented by ACs in early stages and were surgically resect-
able. The 1.5% prevalence of screen-detected lung cancers 
in ITALUNG is substantially in line with those reported in 
observational studies (range, 0.2%–2.7%)12 and RCTs (range, 
0.8%–2.4%)17,18,21,22,24,27,52,53 that recruited elderly heavy smok-
ers and former smokers. Also, the 0.5 mean annual incidence 
rate of screen-detected lung cancers in ITALUNG is comprised 
within the range of previous observational studies and RCTs, 
in which it was consistently lower than 1%.12,13,18,27,33,34,38,53
In ITALUNG AC accounted for 56% of NSCLC at 
baseline and for 88% of NSCLC at subsequent annual repeat 
screening rounds. This predominance of AC in screen-detected 
lung cancers is well established13,18,24,27,34 and presumably 
reflects the capability of LDCT to show small ACs appearing 
as peripheral nodules, whereas, detection with LDCT of cen-
tral tumors developing in the large and medium-size airways, 
which more frequently correspond to squamous carcinomas, 
is suboptimal.54
The majority of the screen-detected NSCLC (23 of 35, 
66%) in the ITALUNG was in stages IA or IB and with a small 
and not statistically significant increase of such low-stage can-
cers from baseline (56%) to subsequent annual repeat (76%) 
screening rounds. Increase of low-stage cancers in LDCT 
screening rounds after baseline (stage shift) is considered 
an indirect element militating in favor of the capability of 
LDCT screening to efficiently impact on lung cancer mortal-
ity, but available data on stage shift in lung cancer screening 
with LDCT are inconsistent.55,56 The predominance of low-
stage NSLCL was observed in all prior observational stud-
ies12 and RCTs.18,21,24,38,53 As expected, screen-detected lung 
cancers in low stages are amenable to surgical resection, and 
this occurred in 35 of 41 of cancers (85%) in the ITALUNG 
trial, which again is in line with other observational studies 
and RCTs.
It is noteworthy that despite the different recruitment 
strategies mentioned above, the variable schedule of the 
screening LDCT rounds with a couple of studies offering 
biennial rather than annual LDCT screening rounds,18,53 and 
some additional minor differences in the target population 
(sex, age, or pack-years distribution), in the LDCT acquisition 
technique (slice collimation ranging between 5 mm17,21 and 
0.75 mm18, implying a possible lower sensitivity to small solid 
and nonsolid nodules in LDCT examinations adopting thicker 
collimation) and in the criteria of positivity of the screening 
test (mean diameter of > 4 or > 5 mm and volume > 50 or > 
60 mm3 for prevalent solid nodules)17,18,22,36 and nodule man-
agement (see below), the yield of the LDCT in terms of rates 
and types of screen-detected lung cancers is remarkably simi-
lar in observational and randomized studies involving elderly 
heavy smokers and former smokers. The low detection rate 
for prevalent and especially incident lung cancers are key ele-
ments in explaining the high cost/effectiveness ratio of lung 
cancer screening with LDCT alone.12,18 This clearly indicates 
that alternative or supplemental strategies for increasing the 
rates of screen-detected lung cancers with LDCT by improving 
the selection of the target population are needed. Inclusion of 
subjects with additional risk factors besides smoking history 
and age, such as occupational asbestos exposure,57 chronic 
obstructive pulmonary disease,58 and especially, inclusion of 
sputum or blood biomarkers40,59,60 in a multidimensional inte-
grated screening strategy should be explored in this context.
In the active arm of the ITALUNG, we observed two 
interval lung cancers, both in advanced stage, over a screen-
ing period of 4 years in 1406 subjects, confirming that the 
most virulent forms of lung cancer can rarely elude LDCT 
screening.18,61 Ascertainment, using cancer registry, of interval 
lung cancer cases in the active arm of ITALUNG trial is still 
underway. However, the above mentioned low rate of interval 
cancers apparently seems to support efficacy of the screening 
procedure in identifying lung cancers.
In ITALUNG, we observed a 30.3% recall rate at 
baseline LDCT screening test, which almost halved (15.7%) 
and stabilized at subsequent annual screening rounds. The 
baseline figures seem higher than the average 20% reported 
in observational studies and RCTs12 with the exception 
of three.62–64 This high recall rate might be because of the 
radiologist learning curve or reflect characteristics of screened 
population. As a matter of fact, at the end of four annual 
screening rounds, 52.7% of subjects in the active arm of the 
ITALUNG were recalled at least once for follow-up LDCT. 
This high cumulative false-positivity rate is in line with the 
data in the Mayo Clinic study in which 69% of the participants 
had at least one false-positive finding over the 5-year 
program,56 and both substantially match the 21% cumulative 
probability of one or more false-positive LDCT examinations 
after one screening and 33% after two, calculated using the 
Kaplan–Meier analysis.23
Reduction of the numbers of follow-up or recall LDCT 
would be valuable, and in our opinion, two basic strategies 
can be hypothesized. The first concerns recent developments 
in the efforts to radiologically characterize solitary lung 
lesions, possibly using CT texture analysis.65,66 The second 
solution entails combination of LDCT with blood or sputum 
biomarker status, which could independently contribute in 
identifying subjects with lethal lung cancers appearing as 
small nodules.40,59
At variance with NLST, in which management of 
screen-detected suspicious nodules was left to the subject’s 
personal health provider, the members of the ITALUNG trial 
adopted a shared protocol for management of positive LDCT 
screening test, which is simple, cheap, and clinically based. In 
fact, it basically relies on double reading for nodule detection 
on LDCT and on operator’s measurement of mean diameter 
to assess lesion growth, on visual assessment of FDG-PET 
uptake of the suspicious nodule, and on CT-guided FNAB 
with ROSE. Other protocols are more technologically oriented 
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because they are based on adoption of software for nodule 
volumetry18,36 and computation of the standardized uptake 
value of FDG-PET,18,36,67–69 and do not include CT-guided 
FNAB.18,22,67–69 One additional distinguishing feature of the 
ITALUNG protocol as compared with other observational 
studies and RCTs is the adoption of antibiotic therapy before 
1-month follow-up LDCT, which is expected to decrease 
the rate of subsequent investigations by revealing the active 
inflammatory nature, especially of incident nodules.47,70
The main instrument used for management of suspi-
cious nodules in the ITALUNG trial was follow-up LDCT, 
which accounted for the majority of further investigations, 
and although associated with additional exposure to low-dose 
radiation,49 often completed the management. In particular, 
the 36% rate of total or partial regression after 1 month of 
antibiotic therapy of prevalent nodules as compared with the 
77% rate of total or partial regression of incident nodules in 
the ITALUNG trial is in line with the 29% disappearance 
or reduction after 1 month of antibiotic therapy of nodules 
detected at baseline screening and with the 74% disappear-
ance or reduction of nodules detected at annual repeat by the 
ELCAP group.70 This is in line with the view that prevalent 
nodules are frequently scars of benign processes, whereas, 
incident nodules frequently correspond to active infective or 
inflammatory processes.
The second most frequently used investigation for nod-
ule management in our study was FDG-PET, which overall was 
carried out in 6.5% of the subjects randomized to the active 
arm who underwent baseline LDCT. This frequency of FDG-
PET is higher than in other observational studies and RCTs 
(range, 2%–4.5%).18,27,33,42,68,71 The excess of FDG-PET in our 
study was related to the high number of FDG-PET examina-
tions performed at baseline (59%), whereas, the mean number 
of FDG-PET at the subsequent annual repeat LDCT screening 
round was 13.6%. By assimilating the indeterminate to the 
positive FDG-PET results, we observed overall 84% sensitiv-
ity and 90% specificity, which are substantially in line with 
those previously reported.37,42,68,69,71
In ITALUNG, 2.4% of subjects randomized to the 
active arm ultimately had FNAB during the screening cycle 
(CT-guided in 37 lesions and ultrasound-guided in 1 lesion) 
as part of their diagnostic workup (38 lesions in 34 sub-
jects). This rate is similar to another LDCT screening studies 
adopting FNAB as part of the protocol,72 but higher than in 
the NELSON (< 1 %)53 and German (1.5 %)24 trials. In the 
majority (89%) of lesions, FNAB was carried out with ROSE, 
which is associated with lower rate of nondiagnostic results, 
in our series it was 11%, as compared with FNAB alone.73 The 
large majority of the subjects (32 of 38) in whom a primary 
lung cancer was ultimately diagnosed at histological exami-
nation underwent preliminary FNAB. If we assimilate the 
inconclusive to negative FNAB results, we obtained a 90% 
sensitivity and 88% specificity. These figures are better than 
those reported both in an LDCT screening program, in which 
21% FNAB yielded unsatisfactory results and 12% FNAB 
were false-positives leading to surgery on benign pathology,72 
and in the clinical practice in which the average sensitivity is 
also 90% but 21% of FNABs produce nondiagnostic results.74 
The unique false-positive result of FNAB in our study, which 
led to surgery for benign pathology was a case of AAH. This 
is considered a preneoplastic lesion and is indistinguishable 
on cytological examination from the former category of bron-
chioloalveolar carcinoma,44,46 which corresponds to the new 
category of early AC, comprising AC in situ, minimally inva-
sive AC, and lepidic predominant AC.75
In a study the combination of volumetry at follow-up 
LDCT with FDG-PET improved the sensitivity for diagnosis 
of lung cancer from 71% (volumetry or FDG-PET alone) to 
90% with a decrease of specificity from 91% to 82%.37 In our 
study the combination of positive FDG-PET and CT-guided 
FNAB invariably predicted primary or secondary lung malig-
nancy, that is, a 100% sensitivity was reached, and no double 
false-positive (at FDG-PET and FNAB) was observed. These 
data, although obtained in a relatively small sample, justify 
the view that CT-guided FNAB with ROSE is very useful for 
management of suspicious nodules detected in LDCT lung 
cancer screening.
The rate of surgical curative therapy in the subjects with 
screen-detected lung cancer in the ITALUNG trial is in line 
with previous data,12,18,34 and reflects the early stages of the 
large majority of the screen-detected lesions.
The 10% rate of surgery for benign lesions in the 
ITALUNG trial is lower than those reported in the majority of 
other screening studies, which can be as high as 33%.76 This low 
rate supports the validity of our management protocol and seems 
noteworthy, especially if one considers that two of the four cases 
referred to surgery for benign lesions corresponded to AAH 
and that in three cases referral to surgery followed protocol 
violations. Strict adherence to a protocol derived by the clinical 
routine and including follow-up LDCT with or without 1 month 
of antibiotic therapy, FDG-PET, and CT-guided FNAB with 
ROSE is expected to further lessen the rate of surgery for benign 
lesions in LDCT screening of lung cancer.29
CONCLUSIONS
The results of the ITALUNG trial indicate that high-risk 
subjects recruited by mail to participate in an RCT offering 
LDCT or usual care for screening of lung cancer show a lower 
adhesion than subjects invited to undergo other consolidated 
population-based screening programs such as those for breast 
or colorectal cancer. However, the adherents randomized to 
receive four annual LDCTs show a high and sustained compli-
ance throughout the screening cycle.
The low rate of screen-detected lung cancers and the 
high recall rate in the ITALUNG trial are in line with those 
of other observational and randomized studies, and confirm 
that improved definition of target population and maybe inte-
gration of the risk stratification with biomarkers are required 
to increase the cost effectiveness of lung cancer screening 
programs.
Adoption of a shared protocol for nodule management 
derived by the clinical routine, including follow-up LDCT 
(with 1 month after antibiotic therapy) and measurement of 
nodule mean diameter, visual assessment of FDG-PET, and 
CT-guided FNAB with ROSE yields high accuracy for pre-
operative detection of lung malignancies, the few surgical 
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interventions for benign lesions being associated with proto-
col violations.
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